MNKD vs NVO
MNKD: MannKind is a biopharmaceutical company specializing in inhaled therapeutic platforms and on-body infusion delivery systems for endocrine and pulmonary conditions. NVO: A global leader in the development of pharmaceutical treatments for diabetes, obesity, and rare chronic diseases, anchored by its prominent GLP-1 therapy portfolio.
Side-by-side fundamentals
| Metric | MNKD | NVO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.42 | $38.18 | |
| Market cap | $1.1B | $206.0B | |
| P/E as of 2026-09-03 | n/a | 11.40 | |
| Net margin FY2025, SEC XBRL | +1.7% | +33.1% | NVO higher |
| Gross margin FY2025, SEC XBRL | n/a | +81.0% | |
| Operating margin FY2025, SEC XBRL | +11.1% | +41.3% | NVO higher |
| ROE FY2025, SEC XBRL | n/a | +52.8% | |
| ROA FY2025, SEC XBRL | +0.7% | +18.9% | NVO higher |
| Debt / equity as of 2026-09-03 | 9.95 | 0.63 | NVO lower |
| Revenue growth (YoY) as of 2026-09-03 | +30.5% | +5.6% | MNKD higher |
| Revenue CAGR (3y) SEC XBRL | +51.8% | +20.4% | MNKD higher |
| Dividend yield as of 2026-09-03 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 0.68 | 0.81 | |
| 1-year return as of 2026-10-08 close | -37.1% | -36.0% | NVO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.